April 9, 2010 – GE Healthcare will present results from its multicenter phase 2 study of flutemetamol at the 4th annual Human Amyloid Imaging (HAI) Meeting in Toronto, Canada. Flutemetamol is a positron emission tomography (PET) imaging agent in development by GE Healthcare, in the field of brain imaging.
The purpose of the phase 2 study was to investigate the efficacy of flutemetamol in differentiating between patients with clinically probable Alzheimer’s disease (AD) and cognitively intact healthy volunteers (HVs). In the study, subjects with a high probability of amyloid (27 AD patients) and a low probability of amyloid (25 healthy subjects) underwent PET imaging with flutemetamol... GE Healthcare's Press Release -
Blog Archive
-
▼
2010
(50)
-
▼
April
(8)
- Octapharma : Trial on Intravenous Immunoglobulin (...
- Siena Biotech : Roche exercises option on compound...
- Avid Radiopharmaceuticals, Cardinal Health : Miles...
- Signum Biosciences : Alzheimer’s Drug Discovery Fo...
- Sun Pharma : USFDA tentative approval for generic ...
- GE Healthcare : positive Phase 2 data with fluteme...
- BELLUS Health : launch of NRM8499 Phase I clinical...
- Takeda & Janssen : About Agreement Reached to Co-m...
-
▼
April
(8)